Chester County News and Community Website
AUDUBON, PA — Globus Medical, Inc. (NYSE: GMED) has announced a major leadership transition alongside preliminary second-quarter results that show continued momentum in its core spine and enabling technologies businesses.
Globus Medical Names Keith Pfeil as CEO, Posts Strong Q2 Sales Growth Read More
WILMINGTON, DE — The Chemours Company (NYSE: CC) issued an updated outlook for the second quarter of 2025, highlighting robust performance across several business segments. Notable gains are projected for …
Chemours Updates Second Quarter 2025 Outlook with Strong Gains in Key Segments Read More
PHILADELPHIA, PA — Five Below, Inc. (NASDAQ: FIVE) announced key leadership changes and an updated financial outlook for the first quarter of fiscal 2025. Co-founder and Executive Chair Tom Vellios …
Five Below Announces Leadership Transition and Raised Q1 2025 Guidance Read More
WILMINGTON, DE — InterDigital, Inc. (Nasdaq: IDCC) has significantly raised its first-quarter 2025 guidance after signing a new multi-year, royalty-bearing license agreement with a leading Chinese smartphone manufacturer. This agreement enhances …
InterDigital Updates Q1 2025 Outlook After Major Smartphone Licensing Deal Read More
LANGHORNE, PA — NEXGEL, Inc. (NASDAQ: NXGL) this week issued a letter to its shareholders outlining robust financial guidance for 2024 and 2025, alongside updates on the company’s strategic growth initiatives …
NEXGEL Projects Over 100% Revenue Growth for Third Consecutive Year Read More
PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced robust preliminary net product revenues for the fourth quarter and full year of 2024, with figures reaching $201 million …
Harmony Biosciences Reports Strong Revenue Growth and Outlines Ambitious 2025 Strategy Read More
YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced preliminary unaudited net product revenue of $22.4 million for the fourth quarter of 2024, driven by sustained growth in prescriptions for XHANCE® (fluticasone …
Optinose Reports $22.4 Million in Preliminary Q4 Revenue for XHANCE Read More
MALVERN, PA — Neuronetics, Inc. (NASDAQ: STIM) has shared its preliminary fourth quarter and full-year revenue figures for 2024, alongside robust guidance and strategic priorities for 2025. The report highlights …
Neuronetics Reports 2024 Revenue Growth, Reveals Optimistic 2025 Guidance Read More
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has revealed significant progress in its pipeline and operations, underscoring its focus on advancing rese-cel, a cell therapy candidate for autoimmune diseases. …
Cabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025 Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (NASDAQ: ABUS) has unveiled its strategic objectives for 2025 alongside an encouraging financial update, emphasizing progress in its efforts to develop a functional cure for …
Arbutus Biopharma Sets Sights on Advancing HBV Cure in 2025 Read More